AU2002309038A1 - Compositions for transmucosal administration containing coenzyme Q as the active ingredient - Google Patents
Compositions for transmucosal administration containing coenzyme Q as the active ingredientInfo
- Publication number
- AU2002309038A1 AU2002309038A1 AU2002309038A AU2002309038A AU2002309038A1 AU 2002309038 A1 AU2002309038 A1 AU 2002309038A1 AU 2002309038 A AU2002309038 A AU 2002309038A AU 2002309038 A AU2002309038 A AU 2002309038A AU 2002309038 A1 AU2002309038 A1 AU 2002309038A1
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- active ingredient
- transmucosal administration
- administration containing
- containing coenzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N Coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 235000017471 coenzyme Q10 Nutrition 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-139605 | 2001-05-10 | ||
JP2001139605 | 2001-05-10 | ||
PCT/JP2002/004476 WO2002092067A1 (en) | 2001-05-10 | 2002-05-08 | Compositions for transmucosal administration containing coenzyme q as the active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002309038A1 true AU2002309038A1 (en) | 2003-05-01 |
AU2002309038B2 AU2002309038B2 (en) | 2007-05-17 |
Family
ID=18986353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002309038A Ceased AU2002309038B2 (en) | 2001-05-10 | 2002-05-08 | Compositions for transmucosal administration containing coenzyme Q as the active ingredient |
Country Status (9)
Country | Link |
---|---|
US (1) | US7754205B2 (en) |
EP (1) | EP1388340B1 (en) |
KR (2) | KR20060103288A (en) |
CN (1) | CN100438862C (en) |
AT (1) | ATE480231T1 (en) |
AU (1) | AU2002309038B2 (en) |
CA (1) | CA2443191A1 (en) |
DE (1) | DE60237597D1 (en) |
WO (1) | WO2002092067A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3742602B2 (en) * | 2001-05-09 | 2006-02-08 | 株式会社カネカ | Stable solution of reduced coenzyme Q |
TW200304372A (en) * | 2002-03-20 | 2003-10-01 | Kanegafuchi Chemical Ind | Compositions for diabetes |
TWI322008B (en) * | 2003-01-31 | 2010-03-21 | Kaneka Corp | Fatigue improving agent including reduced coenzyme q10 |
KR20060100402A (en) * | 2003-10-31 | 2006-09-20 | 가부시키가이샤 가네카 | Composition containing reduced coenzyme q |
KR101420034B1 (en) | 2004-01-22 | 2014-07-17 | 유니버시티 오브 마이애미 | Topical co-enzyme q10 formulations and methodns of use |
US20090081683A1 (en) * | 2005-11-29 | 2009-03-26 | Genelink, Inc. | Kits and Methods for Assessing the Coenzyme Q Reducing Status of a Patient, Including a Patient Ingesting a Statin |
US20090246185A1 (en) * | 2006-03-13 | 2009-10-01 | Kaneka Corporation | Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent |
EP2011498A4 (en) * | 2006-04-10 | 2009-11-11 | Mitsubishi Gas Chemical Co | Brain function-improving agent, and functional food containing the improving agent |
JP2009536215A (en) * | 2006-05-02 | 2009-10-08 | ユニバーシティ オブ マイアミ | Topical coenzyme Q10 formulation and treatment of pain, fatigue, and wounds |
EP3015104A1 (en) | 2008-04-11 | 2016-05-04 | Berg LLC | Methods and use of inducing apoptosis in cancer cells |
KR20120060945A (en) | 2009-05-11 | 2012-06-12 | 버그 바이오시스템즈, 엘엘씨 | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
CA2832324C (en) | 2011-04-04 | 2022-03-15 | Berg Llc | Methods of treating central nervous system tumors |
CN102503798B (en) * | 2011-11-16 | 2014-07-16 | 中国农业科学院蜜蜂研究所 | Method for extracting coenzyme Q 10 from bee pollen and application thereof |
KR101581508B1 (en) * | 2012-12-03 | 2015-12-31 | 가톨릭대학교 산학협력단 | Composition for preventing or treating inflammatory disease or immunological rejection comprising coenzyme Q10 as an effective component |
WO2014088301A1 (en) * | 2012-12-03 | 2014-06-12 | 가톨릭대학교 산학협력단 | Composition for preventing or treating inflammatory diseases or immunological rejection comprising coenzyme q10 as active ingredient |
SG11201508272YA (en) | 2013-04-08 | 2015-11-27 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
AU2014315186B2 (en) | 2013-09-04 | 2020-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
CN110769818A (en) | 2017-05-17 | 2020-02-07 | 博格有限责任公司 | Use of coenzyme Q10 preparation for treating and preventing epidermolysis bullosa |
US11471426B2 (en) | 2019-10-16 | 2022-10-18 | American River Nutrition, Llc | Compositions comprising quinone and/or quinol and methods of preparations and use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH655005A5 (en) * | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY ACTION USABLE IN CARDIAC AND VASCULAR THERAPY. |
US5378461A (en) * | 1991-07-12 | 1995-01-03 | Neigut; Stanley J. | Composition for the topical treatment of skin damage |
US5660835A (en) | 1995-02-24 | 1997-08-26 | East Carolina University | Method of treating adenosine depletion |
US20020032160A1 (en) * | 1995-02-24 | 2002-03-14 | Nyce Jonathan W. | Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels |
JP3889481B2 (en) * | 1996-08-16 | 2007-03-07 | 株式会社カネカ | Pharmaceutical composition |
US6228891B1 (en) * | 1997-02-12 | 2001-05-08 | Mse Pharmazeutika Gmbh | Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
IL122084A (en) * | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
DE19802050A1 (en) | 1998-01-21 | 1999-07-22 | Labtec Gmbh | Peridontal treatment composition providing local oral release of coenzyme Q10 |
US6048886A (en) * | 1998-10-05 | 2000-04-11 | Neigut; Stanley | Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin |
US6200550B1 (en) | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
DE19905880A1 (en) | 1999-02-11 | 2000-08-17 | Mse Pharmazeutika Gmbh | Spray containing ubiquinone Qn |
DE19905879A1 (en) * | 1999-02-11 | 2000-08-17 | Mse Pharmazeutika Gmbh | Ubiquinon Qn used to treat pain |
US20040034107A1 (en) | 1999-02-11 | 2004-02-19 | Mse Pharmazeutika Gmbh | Ubiquinone Qn for the treatment of pain |
US8753675B1 (en) | 2000-01-20 | 2014-06-17 | Raj K. Chopra | Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications |
IT1316997B1 (en) * | 2000-03-02 | 2003-05-26 | Sigma Tau Healthscience Spa | COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF VASCULOPATHIES, WHICH INCLUDES PROPIONYL L-CARNITINE AND COENZYME Q10. |
US6686485B2 (en) * | 2001-04-19 | 2004-02-03 | Daniel David West | Synthesis of coenzyme Q10, ubiquinone |
JP3742602B2 (en) * | 2001-05-09 | 2006-02-08 | 株式会社カネカ | Stable solution of reduced coenzyme Q |
US7708990B2 (en) * | 2004-03-23 | 2010-05-04 | Kaneka Corporation | Coenzyme Q compositions persisting in blood |
-
2002
- 2002-05-08 AT AT02769547T patent/ATE480231T1/en not_active IP Right Cessation
- 2002-05-08 WO PCT/JP2002/004476 patent/WO2002092067A1/en active IP Right Grant
- 2002-05-08 EP EP02769547A patent/EP1388340B1/en not_active Expired - Lifetime
- 2002-05-08 CA CA002443191A patent/CA2443191A1/en not_active Abandoned
- 2002-05-08 AU AU2002309038A patent/AU2002309038B2/en not_active Ceased
- 2002-05-08 CN CNB028092562A patent/CN100438862C/en not_active Expired - Fee Related
- 2002-05-08 KR KR1020067018328A patent/KR20060103288A/en not_active Application Discontinuation
- 2002-05-08 US US10/476,208 patent/US7754205B2/en active Active
- 2002-05-08 DE DE60237597T patent/DE60237597D1/en not_active Expired - Lifetime
- 2002-05-08 KR KR1020037013595A patent/KR100685696B1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL162213A0 (en) | Pharmaceutical compositions containing active vitamin d compounds | |
AU781269C (en) | Pharmaceutical compositions | |
AU2002313236A1 (en) | Medicinal compositions | |
IL161940A0 (en) | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | |
AU2002309038A1 (en) | Compositions for transmucosal administration containing coenzyme Q as the active ingredient | |
AU2001250420A1 (en) | Pharmaceutical compositions | |
AU2002363361A1 (en) | Pharmaceutical compositions containing oxybutynin | |
AU2001274307A1 (en) | Pharmaceutical compositions | |
AU2002341205A1 (en) | Pharmaceutical compositions comprising cyclosporin | |
AU2002257582A1 (en) | Pharmaceutical formulation | |
AU2002337803A1 (en) | Sustained release pharmaceutical compositions | |
AU2002238855A1 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
HUP0400155A3 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
AU2002258221A1 (en) | Medicinal composition | |
AU2002214324A1 (en) | Medicinal compositions | |
AU2002340573A1 (en) | Powdery active ingredient formulations | |
AU2001273919A1 (en) | Pharmaceutical compositions | |
HUP0303636A3 (en) | Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient | |
AU4317500A (en) | Antibiral compositions containing phorbol derivatives as the main active ingredient | |
AU4431400A (en) | Anticancer agents containing ep1 antagonists as the active ingredient | |
AU2002357010A1 (en) | Stabilized active oxygen compositions | |
AU2003216503A1 (en) | Stable pharmaceutical compositions | |
AU2002354460A1 (en) | Medicinal composition | |
EP1199076A3 (en) | Medicament containing tocotrienol as active component | |
HUP0303714A3 (en) | Pharmaceutical compositions for dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient |